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PDiabetes and Detection of CAD: Viewpoint
hould We Screen for Occult Coronary Artery
isease Among Asymptomatic Patients With Diabetes?
arcelo F. Di Carli, MD, FACC,* Rory Hachamovitch, MD, MSC, FACC†
oston, Massachusetts; and Los Angeles, California
Diabetes mellitus predisposes people to premature atherosclerotic coronary artery disease
(CAD). The risk of a myocardial infarction in diabetics without overt evidence of obstructive
CAD matches that of patients without diabetes who have had a previous myocardial
infarction. The available data suggest that occult CAD is a common finding among
asymptomatic diabetics, ranging from 20% to 50%. The diagnostic accuracy of myocardial
perfusion single-photon emission computed tomography (SPECT) in diabetics appears to be
comparable to that observed in nondiabetic individuals. As shown in other patient groups, the
ischemic burden assessed by stress SPECT in subjects with diabetes is also linked to their
increased risk of adverse cardiovascular events. Among patients with normal stress SPECT,
however, those with diabetes are at significantly greater risk than non-diabetics. Testing
diabetics with an abnormal resting electrocardiogram or with evidence of peripheral or carotid
occlusive arterial disease appears to result in an excellent yield of abnormal SPECT findings,
as does testing in the setting of dyspnea. However, recent evidence suggests that achieving an
adequate yield in asymptomatic diabetics without overt evidence of CAD is a greater
challenge. Further investigation of sequential testing strategies is needed in order to identify
an efficient means for screening asymptomatic patients with diabetes. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.0552005;45:50–3) © 2005 by the American College of Cardiology Foundation
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fiabetes mellitus is a major public health problem. It is
stimated that 18.2 million Americans (6.3% of the popu-
ation) have diabetes, of whom 5.2 million are not aware
hat they actually have the disease (1). A total of 95% of
atients have type 2 diabetes. Further, nearly 1.3 million
ndividuals in the U.S. are diagnosed with diabetes each
ear. This dramatic increase in diabetes prevalence is occur-
ing in all age groups, especially in persons 20 to 59 years of
ge (1). In addition, approximately 25% of the U.S. popu-
ation have the metabolic syndrome that greatly increases
he risk of developing diabetes, and this prevalence rises to
40% in patients older than 60 years of age (2). Diabetes
nd its complications add $132 billion in health care and
ndirect (disability, work loss, and premature mortality)
osts to society.
Diabetes is associated with a two- to four-fold increase in
he risk of developing coronary artery disease (CAD). The
isk of a myocardial infarction (MI) in patients with diabetes
nd no evidence of CAD matches that of patients without
iabetes who have had a previous MI (3). In the recent
eport of the Adult Treatment Panel of the National
holesterol Education Program, type 2 diabetes was ac-
orded a CAD risk-equivalent (4). In patients with known
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004, accepted September 21, 2004.AD and diabetes, the rate of death is 70% over 10 years
3). Outcomes are worse in diabetic patients for each
anifestation of CAD. After MI has occurred, the 30-day
ortality rate increases in patients with diabetes by more
han 50% (5). Of those who survive, approximately 50% die
ithin five years after a MI, double the rate found in
on-diabetic patients (6).
In addition, patients with diabetes have a high incidence
f occult CAD, reflected by an increased incidence of silent
I (7) and ischemia (8–10). The lack of warning symptoms
i.e., angina) during infarction and ischemia in patients with
iabetes has been linked to autonomic neuropathy involving
fferent sympathetic fibers, which are considered a key
omponent of the cardiac pain perception pathway. Clinical
tudies have confirmed an association between silent infarc-
ion and ischemia, and autonomic neuropathy (9,11,12).
ecent evidence from the Detection of Ischemia in Asymp-
omatic Diabetics (DIAD) study suggests that more than
ne in five (22%) asymptomatic patients with type 2
iabetes show evidence of ischemia on stress myocardial
erfusion imaging (9). However, other investigators have
eported a substantially higher prevalence of occult CAD
mong asymptomatic diabetics. In a study of 1,427 asymp-
omatic diabetics without prior MI or revascularization
ndergoing nuclear stress testing, Rajagopalan et al. (10)
eported that 826 patients (58%) had an abnormal stress
ingle-photon emission computed tomography (SPECT)
can, and that 261 patients (18%) had a high-risk study as
efined by the combined extent and severity of ischemia
nd/or scar on the nuclear scan. Likewise, a recent study
rom the Cedars-Sinai group (13) examining 1,737 diabetics
ithout prior revascularization or MI—826 asymptomatic,
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2% abnormal SPECT rate with no differences between
symptomatic patients and those with angina. Patients with
yspnea, however, have a significantly higher abnormal
PECT rate (51%). Moreover, this high prevalence of
ccult CAD in asymptomatic diabetics was also similar to
arlier smaller reports (14–16).
These large variations in prevalence and extent of ob-
tructive CAD likely reflect important differences between
he patient populations included in those studies. For
xample, compared with the DIAD trial, the study by
ajagopalan et al. (10) included a higher proportion of
ales (70% vs. 53%), with a longer duration of diabetes (10
s. 8 years), poorer glycemic control (glycosylated hemoglo-
in 7%: 80% vs. 46%), higher prevalence of peripheral
rterial disease reflecting more advanced atherosclerosis
31% vs. 9%), more patients with diabetic dyslipidemia
41% vs. 24%) with less patients on lipid-lowering treatment
19% vs. 47%), more patients with hypertension (71% vs.
1%), and a higher proportion of patients with abnormal Q
aves on resting electrocardiogram (ECG) (9% vs. 0%).
oreover, patients in some of these studies had a clinical
ndication for stress SPECT imaging, and 50% of them
nderwent testing for preoperative evaluation, suggesting
ore advanced disease (10). Taken together, the available
vidence suggests that occult CAD is a common finding
mong asymptomatic patients with diabetes, ranging from
0% in healthier subjects to 50% in patients with more
omplicated diabetes. This poses the challenge of how to
fficiently identify these individuals and target them for
ppropriate therapy.
iagnosing and assessing the extent of CAD in patients
ith diabetes. Few studies have reported on the diagnostic
ccuracy of noninvasive imaging methods for detecting and
ssessing the extent of CAD in patients with diabetes. Kang et
l. (17) reported similar sensitivities and specificities of myo-
ardial perfusion SPECT for detecting angiographic CAD in
iabetic and non-diabetic patients. One relatively common
nding in patients with diabetes is that the extent and severity
f perfusion abnormalities on SPECT imaging frequently
enotes more extensive and severe ischemia than predicted by
oronary angiography. For example, the Mayo Clinic group
eported that 51 of 127 patients (40%) with high-risk nuclear
cans (reflecting extensive and severe ischemia and/or scar)
ndergoing coronary angiography showed relatively mild an-
Abbreviations and Acronyms
ADA  American Diabetes Association
CAD  coronary artery disease
DIAD  Detection of Ischemia in Asymptomatic
Diabetics study
ECG  electrocardiogram
MI  myocardial infarction
SPECT  single-photon emission computed tomographyiographic CAD (i.e., no epicardial disease, or one- to two- eessel disease excluding left main and proximal left anterior
escending coronary artery stenoses). Likewise, 32 of 212
atients (15%) undergoing coronary angiography showed def-
nite mild-to-severe ischemia on the nuclear scan without
vidence of angiographically evident epicardial coronary artery
bstructions. Although these discrepancies between function
nd anatomy have been frequently labeled as “false-positive”
ndings, they likely reflect severe underlying microvascular
ysfunction in the diabetic heart that is underestimated by
onventional coronary angiography. Indeed, there is growing,
onsistent evidence that diabetes causes important alterations
n the regulation of coronary vasodilator function in both
picardial and resistance coronary vessels (18), which are
resent before the appearance of obstructive CAD within the
picardial coronary arteries. These disturbances are indepen-
ent of diabetes-associated lipid abnormalities and hyperten-
ion, and have been linked to both hyperglycemia and insulin
esistance (19,20). In addition, autonomic neuropathy, a com-
on and well-recognized serious complication of diabetes
ellitus, also modulates myocardial perfusion (21) and is
requently associated with perfusion abnormalities (9). Thus,
unctional imaging provides a more accurate assessment of the
otal ischemic burden, especially among diabetic patients with
evere endothelial and smooth muscle cell dysfunction within
he coronary microvasculature.
ssessing risk in patients with diabetes. The observed
xcess ischemic burden in subjects with diabetes is (likely)
inked to their increased risk of adverse cardiovascular events.
s has been the case with other patient populations, a shift has
ccurred toward the use of risk assessment and prognostication
o guide patient management. To date, a number of studies
ave confirmed that stress SPECT provides incremental prog-
ostic value and achieves adequate risk stratification in diabetic
ohorts (13,22–24). Although a normal stress SPECT study is
enerally associated with a low risk (1% annual risk of cardiac
eath or MI) (25), the challenge in a diabetic population is to
efine the elusive “low-risk” patient. To date, reports have
onsistently shown that normal stress SPECT in diabetic
opulations is not associated with this low level of risk and, in
irect comparisons, patients with diabetes are at significantly
reater risk than non-diabetics with normal SPECT
10,13,22–24,26). Similarly, in the setting of an abnormal
PECT, the risk conferred by any given extent and severity of
erfusion abnormality is greater in patients with diabetes than
n non-diabetics. Furthermore, the risk is greater for insulin-
ependent versus non–insulin-dependent diabetes. Generally,
t appears that clinical information adds incremental prognostic
alue over perfusion results and can further risk-stratify
PECT results. These factors include patient gender, age,
resence of peripheral vascular disease or abnormal resting
CG, and the type of diabetes. The prognostic implications of
ymptoms are also important. Compared with asymptomatic
atients, it is unclear if the presence of anginal symptoms is
ssociated with increased risk in patients with diabetes. How-
ver, patients without angina presenting with dyspnea appear
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ng with angina (13).
Our limited knowledge to date in this area indicates
he need to address several issues. Is the greater risk in
atients with diabetes one that can be reduced by
ntervention, medical or otherwise? Although post-
PECT risk is greater in patients with diabetes than in
on-diabetics, patients with diabetes also appear to
ccrue greater survival benefit with revascularization over
edical therapy in the setting of significant ischemia
27). Consequently, perhaps we should shift our focus
rom identification of risk to identification of benefit
27). Because we can improve outcomes in these patients,
ow should we go about identifying candidates for
ggressive management? We must ask how to identify the
iabetic patient in need of testing, and, once identified,
ecide which test and testing algorithm are optimal.
hich asymptomatic diabetics should be screened for
ccult CAD? The American Diabetes Association (ADA)
onsensus guidelines for CAD screening in people with
iabetes recommend testing those patients under several
ircumstances. Testing is recommended in patients with an
bnormal resting ECG or with evidence of peripheral or
arotid occlusive arterial disease (28). The emerging evi-
ence supports the appropriateness of testing in these
atients (10). Indeed, the rate of high-risk scans in a study
rom the Mayo Clinic was 43% among patients with Q
aves on the ECG, 26% among patients with an abnormal
esting ECG, and 28% among those with peripheral arterial
isease (10). The ADA guidelines also recommend testing
n patients with symptoms suspicious of CAD (i.e., chest
ain, dyspnea, fatigue). The data are less compelling for this
ndication. With respect to presenting symptoms, studies
rom both the Mayo Clinic (29) and Cedars-Sinai (13)
roups report similar frequencies of stress SPECT abnor-
ality in patients with and without anginal symptoms. The
atter study identified dyspnea as the only symptom predic-
ive of more frequent abnormal scans and greater risk (13).
In patients with no symptoms nor evidence of cardiac or
eripheral vascular disease, the ADA guidelines recommend
esting only for those individuals who have 2 risk factors
diabetic dyslipidemia, hypertension, active smoking, a fam-
ly history of premature CAD, and albuminuria). In the
IAD study (9), 22% of patients with 2 risk factors (n 
06) had abnormal scans, a rate identical to that among
hose participants with fewer than two risk factors (n 
04). Indeed, 41% of all abnormal SPECT studies in the
IAD trial occurred in the group with fewer than two risk
actors. The rate of high-risk scans was also similar in
atients with 2 versus 2 risk factors. Similarly, Rajago-
alan et al. (10) found that only 17% of patients with 2
isk factors had high-risk scans, a result no different from
he overall cohort.
Hence, it appears that although testing diabetics with an
bnormal resting ECG or with evidence of peripheral or
arotid occlusive arterial disease results in an excellent yield, ps does testing in the setting of dyspnea, achieving an
dequate yield of abnormal SPECT in asymptomatic dia-
etics without overt evidence of CAD is a greater challenge.
n order to augment this low yield, thereby enhancing the
linical- and cost-effectiveness of diagnostic evaluations, it is
robably necessary to enrich the prevalence of disease in this
symptomatic diabetic population before the use of stress
PECT. Two approaches can potentially be used together
r separately to achieve this end. First, the use of an
ggregate score incorporating and weighting multiple risk
actors is superior to an approach of counting the number of
isk factors present (30,31). Indeed, some risk factors appear
o be associated with higher frequencies of high-risk scans
e.g., male, 65 years of age: 31%), whereas others have no
ignificant associations with high-risk scan results (e.g.,
amily history of CAD, insulin use, body mass index) (10).
n addition, the ADA criteria may miss important predic-
ors of risk in patients with diabetes, such as markers of
utonomic function such as the Valsalva heart rate ratio, the
trongest predictor of an abnormal scan in the DIAD study
9). This suggests that a substantial number of asymptom-
tic diabetic patients with few risk factors may have occult
AD, and may be missed on the basis of current ADA
uidelines. Previous studies have shown that incorporating a
linical score into a testing strategy can enhance SPECT
ield and improve cost-effectiveness (32–34). Indeed, a
ecent preliminary report extends some of these findings to
he screening of a diabetic population (35).
A second approach that can be used in conjunction with
r as an alternative to this approach is to utilize a test of
therosclerosis burden for the identification of asymptom-
tic diabetics with a higher likelihood of occult CAD.
revious studies have shown that the use of a calcium score
hreshold (e.g., 400) may identify those individuals with
ntermediate likelihood of SPECT abnormality (36,37).
lthough this threshold may need to be lowered in patients
ith diabetes, it may serve as a first-line test to better define
hich patients may benefit from referral to stress SPECT.
imilarly, intima-medial thickness ratios or ankle-brachial
ndexes may also serve this role. Previous studies have
hown that a sequential testing strategy combining clinical,
ow-cost noninvasive testing and stress SPECT improves
oth the clinical- and cost-effectiveness of testing (34).
onclusions. The epidemic of diabetes has left us with the
hallenge of identifying those asymptomatic individuals
ith diabetes who have silent or occult CAD. Although the
umbers of these patients are significant, not all are candi-
ates for stress SPECT. The emerging evidence seems to
onfirm the potential role of stress SPECT in patients with
reater likelihood of CAD (abnormal resting ECG, evi-
ence of peripheral or carotid occlusive arterial disease,
ymptoms of dyspnea), as well as the low yield of SPECT in
ower-risk asymptomatic diabetic patients. Further investi-
ation of sequential testing strategies is needed in order to
dentify an efficient means for screening this population of
atients.
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